S&P 500   3,760.31 (-1.56%)
DOW   30,844.97 (-1.36%)
QQQ   305.09 (-1.32%)
AAPL   120.51 (-1.27%)
MSFT   226.90 (-0.29%)
FB   259.14 (+1.46%)
GOOGL   2,031.60 (+1.00%)
TSLA   616.50 (-5.62%)
AMZN   2,993.34 (-0.39%)
NVDA   497.34 (-2.90%)
BABA   231.25 (-2.12%)
CGC   31.04 (-6.62%)
GE   13.49 (+0.37%)
MU   84.27 (-5.43%)
NIO   39.57 (-4.72%)
AMD   78.43 (-3.01%)
T   28.95 (+0.80%)
F   12.00 (-1.40%)
ACB   9.76 (-6.69%)
DIS   186.68 (-2.90%)
BA   227.20 (-0.60%)
NFLX   516.77 (-0.75%)
PFE   34.38 (-0.03%)
S&P 500   3,760.31 (-1.56%)
DOW   30,844.97 (-1.36%)
QQQ   305.09 (-1.32%)
AAPL   120.51 (-1.27%)
MSFT   226.90 (-0.29%)
FB   259.14 (+1.46%)
GOOGL   2,031.60 (+1.00%)
TSLA   616.50 (-5.62%)
AMZN   2,993.34 (-0.39%)
NVDA   497.34 (-2.90%)
BABA   231.25 (-2.12%)
CGC   31.04 (-6.62%)
GE   13.49 (+0.37%)
MU   84.27 (-5.43%)
NIO   39.57 (-4.72%)
AMD   78.43 (-3.01%)
T   28.95 (+0.80%)
F   12.00 (-1.40%)
ACB   9.76 (-6.69%)
DIS   186.68 (-2.90%)
BA   227.20 (-0.60%)
NFLX   516.77 (-0.75%)
PFE   34.38 (-0.03%)
S&P 500   3,760.31 (-1.56%)
DOW   30,844.97 (-1.36%)
QQQ   305.09 (-1.32%)
AAPL   120.51 (-1.27%)
MSFT   226.90 (-0.29%)
FB   259.14 (+1.46%)
GOOGL   2,031.60 (+1.00%)
TSLA   616.50 (-5.62%)
AMZN   2,993.34 (-0.39%)
NVDA   497.34 (-2.90%)
BABA   231.25 (-2.12%)
CGC   31.04 (-6.62%)
GE   13.49 (+0.37%)
MU   84.27 (-5.43%)
NIO   39.57 (-4.72%)
AMD   78.43 (-3.01%)
T   28.95 (+0.80%)
F   12.00 (-1.40%)
ACB   9.76 (-6.69%)
DIS   186.68 (-2.90%)
BA   227.20 (-0.60%)
NFLX   516.77 (-0.75%)
PFE   34.38 (-0.03%)
S&P 500   3,760.31 (-1.56%)
DOW   30,844.97 (-1.36%)
QQQ   305.09 (-1.32%)
AAPL   120.51 (-1.27%)
MSFT   226.90 (-0.29%)
FB   259.14 (+1.46%)
GOOGL   2,031.60 (+1.00%)
TSLA   616.50 (-5.62%)
AMZN   2,993.34 (-0.39%)
NVDA   497.34 (-2.90%)
BABA   231.25 (-2.12%)
CGC   31.04 (-6.62%)
GE   13.49 (+0.37%)
MU   84.27 (-5.43%)
NIO   39.57 (-4.72%)
AMD   78.43 (-3.01%)
T   28.95 (+0.80%)
F   12.00 (-1.40%)
ACB   9.76 (-6.69%)
DIS   186.68 (-2.90%)
BA   227.20 (-0.60%)
NFLX   516.77 (-0.75%)
PFE   34.38 (-0.03%)
Log in
NASDAQ:MOR

MorphoSys Competitors

$24.66
-0.09 (-0.36 %)
(As of 03/4/2021 11:40 AM ET)
Add
Compare
Today's Range
$24.59
Now: $24.66
$24.77
50-Day Range
$24.85
MA: $28.21
$30.66
52-Week Range
$18.21
Now: $24.66
$35.73
Volume510 shs
Average Volume45,569 shs
Market Capitalization$3.24 billion
P/E Ratio117.43
Dividend YieldN/A
Beta1.03

Competitors

MorphoSys (NASDAQ:MOR) Vs. ZLAB, TEVA, BHC, GRFS, RDY, and MRTX

Should you be buying MOR stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to MorphoSys, including Zai Lab (ZLAB), Teva Pharmaceutical Industries (TEVA), Bausch Health Companies (BHC), Grifols (GRFS), Dr. Reddy's Laboratories (RDY), and Mirati Therapeutics (MRTX).

MorphoSys (NASDAQ:MOR) and Zai Lab (NASDAQ:ZLAB) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, valuation, earnings, analyst recommendations, risk and institutional ownership.

Valuation & Earnings

This table compares MorphoSys and Zai Lab's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MorphoSys$80.43 million40.34$-115,380,000.00($0.91)-27.10
Zai Lab$12.98 million918.89$-195,070,000.00($3.03)-44.72

MorphoSys has higher revenue and earnings than Zai Lab. Zai Lab is trading at a lower price-to-earnings ratio than MorphoSys, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

3.1% of MorphoSys shares are held by institutional investors. Comparatively, 81.3% of Zai Lab shares are held by institutional investors. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for MorphoSys and Zai Lab, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
MorphoSys05302.38
Zai Lab00503.00

Zai Lab has a consensus target price of $159.00, indicating a potential upside of 17.04%. Given Zai Lab's stronger consensus rating and higher possible upside, analysts plainly believe Zai Lab is more favorable than MorphoSys.

Volatility & Risk

MorphoSys has a beta of 1.03, meaning that its share price is 3% more volatile than the S&P 500. Comparatively, Zai Lab has a beta of 0.95, meaning that its share price is 5% less volatile than the S&P 500.

Profitability

This table compares MorphoSys and Zai Lab's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
MorphoSys8.76%4.51%2.25%
Zai LabN/AN/AN/A

Summary

MorphoSys beats Zai Lab on 8 of the 13 factors compared between the two stocks.

MorphoSys (NASDAQ:MOR) and Teva Pharmaceutical Industries (NYSE:TEVA) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, valuation, earnings, analyst recommendations, risk and institutional ownership.

Valuation & Earnings

This table compares MorphoSys and Teva Pharmaceutical Industries' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MorphoSys$80.43 million40.34$-115,380,000.00($0.91)-27.10
Teva Pharmaceutical Industries$16.89 billion0.68$-998,000,000.00$2.314.56

MorphoSys has higher earnings, but lower revenue than Teva Pharmaceutical Industries. MorphoSys is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

MorphoSys has a beta of 1.03, meaning that its share price is 3% more volatile than the S&P 500. Comparatively, Teva Pharmaceutical Industries has a beta of 1.49, meaning that its share price is 49% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for MorphoSys and Teva Pharmaceutical Industries, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
MorphoSys05302.38
Teva Pharmaceutical Industries29402.13

Teva Pharmaceutical Industries has a consensus target price of $11.6364, indicating a potential upside of 10.19%. Given Teva Pharmaceutical Industries' higher possible upside, analysts plainly believe Teva Pharmaceutical Industries is more favorable than MorphoSys.

Insider and Institutional Ownership

3.1% of MorphoSys shares are held by institutional investors. Comparatively, 51.2% of Teva Pharmaceutical Industries shares are held by institutional investors. 0.6% of Teva Pharmaceutical Industries shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares MorphoSys and Teva Pharmaceutical Industries' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
MorphoSys8.76%4.51%2.25%
Teva Pharmaceutical Industries-24.17%19.32%4.89%

Summary

Teva Pharmaceutical Industries beats MorphoSys on 9 of the 14 factors compared between the two stocks.

MorphoSys (NASDAQ:MOR) and Bausch Health Companies (NYSE:BHC) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, institutional ownership, valuation and profitability.

Valuation and Earnings

This table compares MorphoSys and Bausch Health Companies' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MorphoSys$80.43 million40.34$-115,380,000.00($0.91)-27.10
Bausch Health Companies$8.60 billion1.33$-1,788,000,000.00$4.437.26

MorphoSys has higher earnings, but lower revenue than Bausch Health Companies. MorphoSys is trading at a lower price-to-earnings ratio than Bausch Health Companies, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

MorphoSys has a beta of 1.03, meaning that its stock price is 3% more volatile than the S&P 500. Comparatively, Bausch Health Companies has a beta of 1.47, meaning that its stock price is 47% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current recommendations for MorphoSys and Bausch Health Companies, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
MorphoSys05302.38
Bausch Health Companies05702.58

Bausch Health Companies has a consensus target price of $31.50, indicating a potential downside of 2.17%. Given Bausch Health Companies' stronger consensus rating and higher possible upside, analysts clearly believe Bausch Health Companies is more favorable than MorphoSys.

Insider & Institutional Ownership

3.1% of MorphoSys shares are held by institutional investors. Comparatively, 62.9% of Bausch Health Companies shares are held by institutional investors. 12.1% of Bausch Health Companies shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares MorphoSys and Bausch Health Companies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
MorphoSys8.76%4.51%2.25%
Bausch Health Companies-23.92%173.20%4.21%

Summary

Bausch Health Companies beats MorphoSys on 10 of the 14 factors compared between the two stocks.

MorphoSys (NASDAQ:MOR) and Grifols (NASDAQ:GRFS) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, institutional ownership, valuation and profitability.

Valuation and Earnings

This table compares MorphoSys and Grifols' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MorphoSys$80.43 million40.34$-115,380,000.00($0.91)-27.10
Grifols$5.71 billion1.84$700.16 million$1.1713.09

Grifols has higher revenue and earnings than MorphoSys. MorphoSys is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

MorphoSys has a beta of 1.03, meaning that its stock price is 3% more volatile than the S&P 500. Comparatively, Grifols has a beta of 0.59, meaning that its stock price is 41% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current recommendations for MorphoSys and Grifols, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
MorphoSys05302.38
Grifols05302.38

Insider & Institutional Ownership

3.1% of MorphoSys shares are held by institutional investors. Comparatively, 15.2% of Grifols shares are held by institutional investors. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares MorphoSys and Grifols' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
MorphoSys8.76%4.51%2.25%
Grifols12.79%10.65%4.79%

Summary

Grifols beats MorphoSys on 7 of the 10 factors compared between the two stocks.

MorphoSys (NASDAQ:MOR) and Dr. Reddy's Laboratories (NYSE:RDY) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, institutional ownership, valuation and profitability.

Valuation and Earnings

This table compares MorphoSys and Dr. Reddy's Laboratories' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MorphoSys$80.43 million40.34$-115,380,000.00($0.91)-27.10
Dr. Reddy's Laboratories$2.32 billion4.43$259 million$2.7922.11

Dr. Reddy's Laboratories has higher revenue and earnings than MorphoSys. MorphoSys is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

MorphoSys has a beta of 1.03, meaning that its stock price is 3% more volatile than the S&P 500. Comparatively, Dr. Reddy's Laboratories has a beta of 0.41, meaning that its stock price is 59% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current recommendations for MorphoSys and Dr. Reddy's Laboratories, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
MorphoSys05302.38
Dr. Reddy's Laboratories00403.00

Dr. Reddy's Laboratories has a consensus target price of $70.00, indicating a potential upside of 13.34%. Given Dr. Reddy's Laboratories' stronger consensus rating and higher possible upside, analysts clearly believe Dr. Reddy's Laboratories is more favorable than MorphoSys.

Insider & Institutional Ownership

3.1% of MorphoSys shares are held by institutional investors. Comparatively, 12.9% of Dr. Reddy's Laboratories shares are held by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares MorphoSys and Dr. Reddy's Laboratories' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
MorphoSys8.76%4.51%2.25%
Dr. Reddy's Laboratories8.23%16.33%10.79%

Summary

Dr. Reddy's Laboratories beats MorphoSys on 10 of the 14 factors compared between the two stocks.

MorphoSys (NASDAQ:MOR) and Mirati Therapeutics (NASDAQ:MRTX) are both mid-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, institutional ownership, valuation and profitability.

Valuation and Earnings

This table compares MorphoSys and Mirati Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MorphoSys$80.43 million40.34$-115,380,000.00($0.91)-27.10
Mirati Therapeutics$3.34 million2,762.28$-213,260,000.00($5.69)-32.02

MorphoSys has higher revenue and earnings than Mirati Therapeutics. Mirati Therapeutics is trading at a lower price-to-earnings ratio than MorphoSys, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

MorphoSys has a beta of 1.03, meaning that its stock price is 3% more volatile than the S&P 500. Comparatively, Mirati Therapeutics has a beta of 1.64, meaning that its stock price is 64% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current recommendations for MorphoSys and Mirati Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
MorphoSys05302.38
Mirati Therapeutics151002.56

Mirati Therapeutics has a consensus target price of $218.5714, indicating a potential upside of 19.78%. Given Mirati Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Mirati Therapeutics is more favorable than MorphoSys.

Insider & Institutional Ownership

3.1% of MorphoSys shares are held by institutional investors. Comparatively, 94.9% of Mirati Therapeutics shares are held by institutional investors. 4.1% of Mirati Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares MorphoSys and Mirati Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
MorphoSys8.76%4.51%2.25%
Mirati TherapeuticsN/A-60.01%-54.21%

Ad Dear Wallstreet
This may be 2021's Hottest Ground Floor Story
This oil company is creating trust in the massive trillion dollar trading world

MorphoSys Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Zai Lab logo
ZLAB
Zai Lab
1.4$135.50-3.8%$12.38 billion$12.98 million-44.72Analyst Revision
News Coverage
Teva Pharmaceutical Industries logo
TEVA
Teva Pharmaceutical Industries
1.4$10.54-3.6%$11.93 billion$16.89 billion-2.86Gap Up
Bausch Health Companies logo
BHC
Bausch Health Companies
1.7$32.14-1.3%$11.56 billion$8.60 billion-5.90Analyst Report
Analyst Revision
Grifols logo
GRFS
Grifols
1.2$15.31-4.5%$11.00 billion$5.71 billion13.67Analyst Report
Dr. Reddy's Laboratories logo
RDY
Dr. Reddy's Laboratories
1.5$61.70-1.2%$10.13 billion$2.32 billion50.99
Mirati Therapeutics logo
MRTX
Mirati Therapeutics
1.6$182.21-3.7%$9.56 billion$3.34 million-23.66Earnings Announcement
Analyst Report
Analyst Revision
BridgeBio Pharma logo
BBIO
BridgeBio Pharma
1.6$60.84-5.0%$9.52 billion$40.56 million-17.84Analyst Report
Analyst Revision
Jazz Pharmaceuticals logo
JAZZ
Jazz Pharmaceuticals
2.1$162.13-0.5%$9.18 billion$2.16 billion51.15Analyst Report
Increase in Short Interest
Analyst Revision
Ultragenyx Pharmaceutical logo
RARE
Ultragenyx Pharmaceutical
1.2$120.47-4.0%$8.39 billion$103.71 million-27.44Analyst Report
Insider Selling
News Coverage
Ascendis Pharma A/S logo
ASND
Ascendis Pharma A/S
1.3$153.52-0.4%$8.17 billion$14.98 million-18.70
Arrowhead Pharmaceuticals logo
ARWR
Arrowhead Pharmaceuticals
1.3$70.66-6.8%$7.83 billion$87.99 million-84.12
ACADIA Pharmaceuticals logo
ACAD
ACADIA Pharmaceuticals
1.8$46.51-2.0%$7.59 billion$339.08 million-27.04Analyst Report
Analyst Revision
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.4$51.32-2.9%$7.44 billion$1.12 billion106.92Analyst Upgrade
Analyst Revision
United Therapeutics logo
UTHR
United Therapeutics
1.9$160.46-1.7%$7.27 billion$1.45 billion15.18Analyst Report
Analyst Revision
Schrödinger logo
SDGR
Schrödinger
1.5$73.15-35.5%$6.89 billion$85.54 million0.00Gap Up
Sarepta Therapeutics logo
SRPT
Sarepta Therapeutics
1.9$84.55-3.0%$6.87 billion$380.83 million-10.81Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
GW Pharmaceuticals logo
GWPH
GW Pharmaceuticals
1.5$214.69-0.0%$6.67 billion$311.33 million-124.82Decrease in Short Interest
Maravai LifeSciences logo
MRVI
Maravai LifeSciences
1.9$33.15-9.6%$6.13 billionN/A0.00Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Allakos logo
ALLK
Allakos
1.7$109.00-2.2%$5.85 billionN/A-39.78Earnings Announcement
Insider Selling
Analyst Revision
News Coverage
AVIR
Atea Pharmaceuticals
1.7$63.44-11.3%$5.83 billionN/A0.00Upcoming Earnings
Decrease in Short Interest
Gap Up
Perrigo logo
PRGO
Perrigo
2.6$40.88-1.0%$5.63 billion$4.84 billion-681.22Earnings Announcement
Analyst Revision
TG Therapeutics logo
TGTX
TG Therapeutics
1.8$41.77-2.3%$5.62 billion$150,000.00-19.70Earnings Announcement
Analyst Revision
News Coverage
Blueprint Medicines logo
BPMC
Blueprint Medicines
1.5$91.71-1.4%$5.39 billion$66.51 million16.92
Galapagos logo
GLPG
Galapagos
1.3$86.68-5.0%$5.38 billion$1.00 billion-13.13Analyst Report
Gap Down
Turning Point Therapeutics logo
TPTX
Turning Point Therapeutics
1.9$102.43-9.0%$5.38 billionN/A-29.18Earnings Announcement
Analyst Upgrade
Analyst Revision
News Coverage
Emergent BioSolutions logo
EBS
Emergent BioSolutions
1.8$92.50-2.4%$5.05 billion$1.11 billion29.74Analyst Upgrade
Eidos Therapeutics logo
EIDX
Eidos Therapeutics
1.0$122.21-0.0%$4.75 billion$26.69 million-46.12
Biohaven Pharmaceutical logo
BHVN
Biohaven Pharmaceutical
1.8$78.95-0.4%$4.75 billionN/A-6.43Earnings Announcement
Analyst Report
Insider Buying
Analyst Revision
News Coverage
Gap Down
Sage Therapeutics logo
SAGE
Sage Therapeutics
1.4$71.58-6.4%$4.45 billion$6.87 million-6.92Analyst Report
Analyst Revision
Gap Up
Reata Pharmaceuticals logo
RETA
Reata Pharmaceuticals
1.4$125.18-3.7%$4.43 billion$26.52 million-11.03Earnings Announcement
Analyst Revision
News Coverage
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.3$71.48-2.5%$4.42 billion$806.43 million-10.12Analyst Report
News Coverage
IMAB
I-Mab
1.1$56.32-8.7%$4.41 billion$4.31 million-1.95Analyst Report
News Coverage
Gap Up
Hutchison China MediTech logo
HCM
Hutchison China MediTech
1.4$28.35-5.9%$4.37 billion$204.89 million-35.44News Coverage
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$58.31-6.9%$4.32 billion$36.13 million-87.03Earnings Announcement
Analyst Report
Insider Selling
Decrease in Short Interest
Analyst Revision
News Coverage
Gap Up
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.3$22.47-4.3%$4.27 billion$114.62 million-9.06Earnings Announcement
Analyst Report
Analyst Revision
PTC Therapeutics logo
PTCT
PTC Therapeutics
1.3$57.25-0.4%$4.01 billion$306.98 million-8.19Earnings Announcement
Analyst Revision
Gap Up
Insmed logo
INSM
Insmed
1.2$37.61-0.8%$3.91 billion$136.47 million-14.47Earnings Announcement
Analyst Report
Arvinas logo
ARVN
Arvinas
1.9$71.25-6.6%$3.68 billion$42.98 million-27.83Earnings Announcement
Analyst Downgrade
Insider Selling
Unusual Options Activity
Analyst Revision
Apellis Pharmaceuticals logo
APLS
Apellis Pharmaceuticals
1.6$45.23-0.6%$3.66 billionN/A-6.10Analyst Report
LEGN
Legend Biotech
1.2$24.87-3.7%$3.40 billion$64.39 million0.00Increase in Short Interest
Karuna Therapeutics logo
KRTX
Karuna Therapeutics
1.6$115.53-5.3%$3.29 billionN/A-57.48Earnings Announcement
Analyst Report
Analyst Revision
Agios Pharmaceuticals logo
AGIO
Agios Pharmaceuticals
1.5$46.35-0.5%$3.21 billion$117.91 million-9.40Analyst Downgrade
Analyst Revision
FibroGen logo
FGEN
FibroGen
1.6$33.77-1.7%$3.13 billion$256.58 million-12.94Earnings Announcement
Analyst Downgrade
Unusual Options Activity
Analyst Revision
ALX Oncology logo
ALXO
ALX Oncology
1.9$79.62-5.3%$3.11 billionN/A0.00Decrease in Short Interest
Pacira BioSciences logo
PCRX
Pacira BioSciences
1.9$69.27-0.1%$3.01 billion$421.03 million24.39Analyst Report
News Coverage
Alkermes logo
ALKS
Alkermes
1.2$18.55-0.5%$2.97 billion$1.17 billion-40.33Analyst Revision
Rocket Pharmaceuticals logo
RCKT
Rocket Pharmaceuticals
1.6$52.59-0.6%$2.92 billionN/A-28.90Earnings Announcement
Analyst Report
Analyst Revision
Gap Up
Viela Bio logo
VIE
Viela Bio
0.8$52.99-0.0%$2.91 billion$50 million-7.55Earnings Announcement
Decrease in Short Interest
Analyst Revision
OPKO Health logo
OPK
OPKO Health
1.9$4.19-3.1%$2.89 billion$901.90 million-23.28
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.6$24.15-1.1%$2.86 billion$306.49 million27.14
This page was last updated on 3/4/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.